Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of zilucoplan (Zilbrysq) in pediatric generalized myasthenia gravis
2022-502073-42-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Dec 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent serious adverse events and 2 more. Planned start Dec 2023; status: authorised.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2022-502073-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502073-42-00.